Latest News

Covagen Adds Baxter Ventures as Investor.

ZURICH-SCHLIEREN, Switzerland, Feb 19, 2014 – Seroba Kernel investee company, Covagen, today announced it has added Baxter Ventures as an investor in its Series B financing round raising the total to CHF 44.9 million. The Series B includes an option for all existing investors to invest an additional CHF 14 million in the future, potentially increasing the total amount of this...




Ario Pharma Commences Phase IIa Trial of TRPV1 Inhibitor for Cough associated with Chronic Obstructive Pulmonary Disease.

Cambridge, UK, 11 February 2014. Ario Pharma Ltd, the Cambridge biopharmaceutical company developing innovative new approaches to treat respiratory disease, announced today that it has commenced a Phase IIa study of its TRPV1 antagonist, XEN-0501, for the treatment and prevention of cough in patients with chronic obstructive pulmonary disease (COPD). Persistent cough in COPD and...


< back to home page